Mission Bay Capital LLC uses capital and expertise to help entrepreneurs emerging from the University of California change the world. We begin with the conviction that more of the creativity of the University of California can directly benefit society. Universities have an obligation to meet public needs for new sources of energy, new solutions for patients, and ultimately the formation of whole new industries.
MBC will help launch companies that meet these needs. Our success will redress social challenges, replenish future funds, and ultimately build a research and educational endowment for QB3 (California Institute for Quantitative Biosciences) to drive the development of the next generation of innovations.
MBC will help launch companies that meet these needs. Our success will redress social challenges, replenish future funds, and ultimately build a research and educational endowment for QB3 (California Institute for Quantitative Biosciences) to drive the development of the next generation of innovations.
Location: United States, California, San Francisco
Employees: 11-50
Founded date: 2009
Investors 1
| Date | Name | Website |
| - | Scientia V... | scientiavc... |
Mentions in press and media 10
| Date | Title | Description |
| 11.03.2024 | Nitrase Therapeutics Unveils Pioneering Antibody Candidate for Parkinson’s Disease Based on Nitration Discovery in Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conferen... | -Nitrase’s first-in-class antibody found to significantly delay progression of Parkinson’s disease in preclinical models by blocking the propagation of pathogenic nitrated synuclein -Advancing development candidate NDC-0524 into IND-enablin... |
| 22.07.2021 | Plant-based cheesemaker Nobell Foods nets $75m from a16z, AgFunder & Breakthrough Energy | Disclosure: AFN’s parent company AgFunder is an investor in Nobell Foods. Alt-protein startup Nobell Foods has raised $75 million in a Series B round led by Breakthrough Energy Ventures (BEV) – the climate-focused investment group founded b... |
| 17.09.2019 | Life science-focused Mission Bay Capital raises $60m for Fund III | San Francisco-based VC Mission Bay Capital has raised $60m for the final close of its third early-stage life-science fun |
| 16.09.2019 | Mission Bay Capital Closes Fund III, at $60M | Mission Bay Capital, a San Francisco, CA-based early-stage life-science venture capital firm investing in innovative entrepreneurs working on vital medical and environmental challenges, closed its third fund, at $60M. Investors include Aste... |
| 05.12.2017 | Asilomar Bio Raises $12m Series B for Chemical Yield Enhancer | Asilomar Bio, a San Francisco-based maker of chemical crop inputs has raised a $12.25 million Series B Round to bring it’s first chemical yield enhancement product to market. This announcement comes on the heels of a licensing agreement wit... |
| 08.09.2016 | Chrono Therapeutics raises $47.6M for smoking cessation wearable to deliver nicotine fix before you wake | The wearable also has a “crave” button users can press that records the moment they want a cigarette and triggers an immediate coaching message through the app to help the user get through the moment without smoking. There is also a behavio... |
| 12.05.2015 | Mission Bay Capital Closes $25M Life Sciences Fund | Mission Bay Capital, LLC (MBC), a San Francisco, CA-based seed-stage venture firm investing in life science companies emerging from the University of California and the San Francisco Bay Area ecosystem, closed its latest fund at $25m. Inves... |
| 20.05.2013 | eFFECTOR Therapeutics Raises $45 Million in Series A Financing | eFFECTOR Therapeutics Raises $45 Million in Series A Financing Company to Focus on Small Molecule Selective Regulators of Protein Synthesis for Cancer San Diego, CA – May 20, 2013 – eFFECTOR Therapeutics, a newly established biopharmaceutic... |
| 20.05.2013 | eFFECTOR Therapeutics Completes $45M Series A Financing | eFFECTOR Therapeutics, a San Diego, CA-based newly formed biopharmaceutical company, completed a $45m Series A financing. Backers included U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage... |
| - | Chrono Therapeutics raises $47.6M for smoking cessation wearable to deliver nicotine fix before you wake | Smoking cessation is a big priority for self-insured employer programs and payers, particularly since most payers are inclined to reimburse for these programs because of the impact of smoking on health. The challenge, as Chrono Therapeutics... |